Orthocell (ASX:OCC) has signed a global exclusive license and manufacturing agreement for its FDA-cleared dental product, Striate+™, with BioHorizons Implant Systems Inc – one of the largest dental implant companies in the world.
Remplir™ Channel 7 News feature
Clinical trial participant Damian Hall was featured in a national news story by Channel 7 News Reporter, Alison Fan, to discuss his path to continued mobility following a nerve repair procedure with Remplir™.
Quarterly Report | Period To 31 March 2022
Orthocell has today published its Quarterly Report for the period ended 31 March 2022.
Standout achievements for this Quarter include:
- Remplir™ nerve repair device receives Australian regulatory approval for introduction into the Australian nerve repair and regeneration market
- Application for inclusion of Remplir™ on the Prostheses List on track for submission in Q2 CY2022
- Final Remplir™ 24 month results of all patients in the nerve regeneration study on track for Q2 CY2022
- SignificantStriate+™ US market entry progress with sale of over 1,500 Striate+™ units achieved, and commencement of facility upgrade to enable scale up Striate+™ manufacturing capacity to >100,000 units per year
- Striate+™ distributor discussions progressed and the Company is in advanced discussions to engage its first US distributor and establish Striate+™ as the premium dental membrane
- The final data from the OrthoATI™ Phase 2a study on track for Q2 CY2022
VIDEO | Proactive Investors – March 2022
Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about passing a key milestone in the OrthoATI™ rotator cuff tendon study.
TGA Approval for Remplir™
Orthocell’s Remplir™ device has gained Australian regulatory (Therapeutics Goods Administration) approval.
Striate+™ Market Update
Orthocell’s Striate+™ dental membrane, which facilitates high quality and efficient bone and tissue repair, is gaining commercial momentum.
Meet Orthocell’s Quality Director, Monique Cannon
On International Day of Women In Science, we’re proud to shine a spotlight on Orthocell’s Quality Director, Monique Cannon.
Quarterly Report – Period To December 2021
Orthocell (ASX $OCC) has today published its Quarterly Report for the period ended 31 December 2021.
RADIO INTERVIEW | Bulls N’ Bears Report
Orthocell (ASX $OCC) MD, Paul Anderson, was interviewed by Matt Birney on the Bulls N’ Bears Report about our latest OrthoATI™ clinical data.
The West Australian | Orthocell’s tendon injury treatment a game-changer, clinical trial finds
Orthocell (ASX $OCC) has been featured in The West Australian in a story titled, “Orthocell’s tendon injury treatment a game-changer, clinical trial finds”, following the release of positive clinical data for our OrthoATI™ cell therapy last week.